Jeremy Skillington of Poolbeg Pharma: Early data read out for POLB 001 indicates a successful LPS human challenge trial
Episode 1113, Jan 09, 2023, 07:58 AM
Jeremy Skillington, CEO of Poolbeg Pharma #POLB discusses the positive initial data analysis in POLB 001 LPS Challenge Trial and says a full data read-out is expected in Q2 2023 following a final quality check of the unblinded data.
Highlights
- POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo
- A clear dose-response relationship was demonstrated
- Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported
- Full data read-out expected in Q2 2023 following a final quality check of the unblinded data
To read the full RNS click here
Highlights
- POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo
- A clear dose-response relationship was demonstrated
- Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported
- Full data read-out expected in Q2 2023 following a final quality check of the unblinded data
To read the full RNS click here